Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 009″]
Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology industry. Today, Anido expects big things for Aerie Pharmaceuticals, a clinical-stage pharmaceutical company with two promising treatments for glaucoma in late clinical trials.
Podcast Guest
![Vince-Anido](https://ois.net/wp-content/uploads/2015/12/Vince-Anido.jpg)
Vicente Anido, Jr., PhD
Vicente Anido, Jr., PhD currently serves as CEO and Chairman of the Board of Aerie Pharmaceuticals, Inc., a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.